Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
Rhea-AI Summary
Anika (NASDAQ: ANIK) will release its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. Management will host a conference call at 8:30 a.m. ET to review results and business highlights, with access via domestic and international dial-in numbers and a live webcast on the Investor Relations section of its website. An archived replay and presentation materials will be available online shortly after the call.
Positive
- None.
Negative
- None.
News Market Reaction – ANIK
In the Jul 16 session, ANIK declined 0.69%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 15 | Earnings date notice | Neutral | +0.7% | Scheduled Q1 2026 results release before open with 8:30 a.m. call. |
| Feb 12 | Earnings date notice | Neutral | +1.5% | Announced Q4 and full-year 2025 results timing and follow-on conference call. |
| Oct 23 | Earnings date notice | Neutral | +3.7% | Set Q3 2025 results release date and investor conference call details. |
| Jul 16 | Earnings date notice | Neutral | +0.5% | Scheduled Q2 2025 results, including pre-open release and 8:30 a.m. call. |
| Apr 25 | Earnings date notice | Neutral | +0.4% | Announced Q1 2025 results timing and access information for conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings date announcements have typically coincided with small positive share moves for ANIK.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2026 financial results before the opening of the market on Wednesday, July 29, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 60388. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.anika.com. The call will be archived and accessible on the same website shortly after its conclusion.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Executive Director, Corporate Development and Investor Relations
investorrelations@anika.com
